thanks for a rational response, although I don't think you've hit the mark on where ARQ-197 fits in, it's clear that ARQ-197 is not being pursued as a genetic variant targeted treatment, rather it appears to be working well as a met 'high' co-therapy along with the targeted agent (e.g., tarceva for the current p3 trials). Something like 20% of the EGFR gene variants (KRAS also has a met high population see the first link in my above post) exhibit progression associated met high characteristics. This puts ARQ-197 in a unique position, 1) it is not being targeted at a specific gene variatant, and while this is counter to the prevailing first line strategy for cancer treatment (where a one size fits is out of date), nevertheless in the limited NSCLC domain, a met high inhibitor co-therapy can have an important contributing theraputic role. Hence, as I read it, ARQ-197 is indeeded being tested to play this supporting role across the genotype variant board. This is clearly different to xalkoria (except for METmab of course) vis a vis xalkoria, an potential with something like a 20% market share of all NSCLC, not 4%. That's the point.